Findings

What do systematic reviews say?

1,060 questions · 1,105 findings · 84 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 434 · 39.3%GRADE not reported 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Intervention not reported

Individuals in euthyroid state [measured by serum thyroid hormone levels within the normal range]

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Intervention not reported

Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment]

It is very uncertain whether the intervention changes recurrence of hyperthyroidism (relapse) [measured by serum thyroid… (very low certainty).

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
RR 0.2 [0.01, 2.66]
2 studies · 417 participants
Very low

Intervention not reported

Adverse events other than development or worsening of Graves' disease (a) Hypothyroidism [measured by TSH and/or thyroid hormones] (b) Drug reactions

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Very low

Intervention not reported

All‐cause mortality

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 425 participants
GRADE not reported

Intervention not reported

Socioeconomic effects [costs per patient, based on the official hospital reimbursement system in Sweden]

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Subcutaneous insulin lispro vs intravenous regular insulin

All‐cause mortality (N) Mean hospital stay: 2‐7 days

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 156 participants
Moderate

Subcutaneous insulin aspart vs intravenous regular insulin

Morbidity

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

Adverse events other than hypoglycaemic episodes

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

Time to resolution of diabetic ketoacidosis (h) Mean hospital stay: 3‐5 days

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Subcutaneous insulin aspart vs intravenous regular insulin

Patient satisfaction

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

Length of hospital stay

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low

Subcutaneous insulin lispro vs intravenous regular insulin

Hypoglycaemic episodes

Subcutaneous insulin lispro showed no clear difference in hypoglycaemic episodes (N) Mean hospital stay: 2‐7 days compared with intravenous regular insulin (low certainty).

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
RR 0.59 [0.23, 1.52]
4 studies · 156 participants
Low

Subcutaneous insulin lispro vs intravenous regular insulin

Length of hospital stay

2 findings from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 96 participants
GRADE not reported
Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 90 participants
Low

Subcutaneous insulin lispro vs intravenous regular insulin

Adverse events other than hypoglycaemic episodes

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous insulin lispro vs intravenous regular insulin

Time to resolution of diabetic ketoacidosis (h) Mean hospital stay: 2‐4 days

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 90 participants
Very low

Subcutaneous insulin lispro vs intravenous regular insulin

Patient satisfaction

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

All‐cause mortality (N) Mean hospital stay: 2‐7 days

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low

Subcutaneous insulin aspart vs intravenous regular insulin

Hypoglycaemic episodes

Subcutaneous insulin aspart showed no clear difference in hypoglycaemic episodes (N) Mean hospital stay: 3‐5 days compared with intravenous regular insulin (low certainty).

1 finding from 1 review

Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
RR 1 [0.07, 14.55]
1 study · 30 participants
Low

Intervention not reported

Diabetes‐related complications · adults with type 2 diabetes and severe mental illness

The review found no eligible studies for this question.

1 finding from 1 review

Self management interventions for type 2 diabetes in adult people with severe mental illness 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · adults with type 2 diabetes and severe mental illness

The review found no eligible studies for this question.

1 finding from 1 review

Self management interventions for type 2 diabetes in adult people with severe mental illness 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found